Trials / Completed
CompletedNCT02720263
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
A Phase 1 Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending oral doses of ASP4345 in patients with schizophrenia. In addition, this study will evaluate the pharmacokinetics of multiple ascending oral doses of ASP4345 in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP4345 | Oral |
| DRUG | Matching Placebo | Oral |
Timeline
- Start date
- 2016-03-28
- Primary completion
- 2017-06-08
- Completion
- 2017-06-08
- First posted
- 2016-03-25
- Last updated
- 2024-10-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02720263. Inclusion in this directory is not an endorsement.